Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant – United States, February 14-March 27, 20222022년 2월 14일-3월 27일, 미국, 2022년 2월 14일-3월 27일, 미국, 2022년 2월 14일-3월 27일Article Published on 2022-05-062022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI accounted Ad26 analyzed B.1.1.529 BNT162b2 booster dose booster doses Booster vaccine cause CDC conjunction Coverage COVID-19 COVID-19 vaccination COVID-19 vaccine Decline defined dose Effectiveness eligible greater home Immunocompromised include Infection infection with SARS-CoV-2 isolates Johnson & Johnson morbidity and mortality mRNA mRNA vaccine mRNA-1273 network NHSN Nursing nursing home omicron Omicron variant Pfizer-BioNTech Preventing primary dose PROTECT receipt receive reported resident Safety SARS-CoV-2 sequenced Surveillance United States vaccination Vaccine Vaccine-induced immunity Variability variant variants virus Weekly [DOI] 10.15585/mmwr.mm7118a4 PMC 바로가기 [Article Type] Article
Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France프랑스에서 백신 접종 6개월 후 1차 의료 종사자들 사이에서 SARS-CoV-2 IgG 항체 및 SARS-CoV-2 IgG 중화 활성과 관련된 인자의 혈청유병률Article Published on 2022-05-032022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법, [키워드] 95% CI 95% confidence interval activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 antibody association booster dose booster doses capillary blood Care conducted coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 COVID-19 vaccine cross-sectional survey Factor Factors France Health Health care Health care worker health care workers highlight Immunoglobulin Immunoglobulin G immunoglobulin G response Month multivariate N protein Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody nucleocapsid Odds ratio participant presence of antibody primary care Primary Health Care Protein questionnaire regression analysis respiratory S protein S-1 SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 IgG SARS-COV-2 infection sera Seroprevalence Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus significantly significantly more tested the N protein the S protein vaccination vaccine dose vaccine doses worker [DOI] 10.3390/v14050957 PMC 바로가기 [Article Type] Article
Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab나탈리주맙으로 치료받은 다발성 경화증 환자에서 BNT162b2 mRNA COVID-19 백신에 대한 6개월 체액 반응Article Published on 2022-05-012022-09-11 Journal: Neurological Sciences [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] A significant reduction age All participants BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine booster dose booster doses both group both groups clinician collected comparable COVID-19 COVID-19 vaccination COVID-19 vaccine Cutoff develop DiaSorin first dose healthy humoral humoral immune response Humoral response IgG IgG antibodies IgG antibody immune response investigated LIAISON limit maintain mRNA mRNA vaccine Multiple multiple sclerosis Natalizumab of BNT162b2 Participants Patient positive positive IgG antibodies SARS-CoV-2 SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody SARS-CoV-2 spike protein SARS-CoV-2 vaccine serum sample serum samples Spike protein treated Vaccine [DOI] 10.1007/s10072-022-05940-0 PMC 바로가기 [Article Type] Article
An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey터키 의료 종사자의 코로나백 2차 접종 후 항체 반응 및 BNT162b2 또는 코로나백 추가 접종 후 체액성 반응 분석Article Published on 2022-05-012022-09-11 Journal: Journal of medical virology [Category] Fulltext, MERS, 변종, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration age Analysis Anti-RBD IgG anti-receptor-binding domain antibody antibody levels Antibody Response asked blood draw BNT162b2 booster booster dose booster doses chronic disease circulating variants Complete CoronaVac coronavirus dose evaluated Follow-up groups healthcare worker Healthcare workers Heterologous heterologous vaccination homologous or heterologous humoral Humoral response IgG Immunoglobulin Immunoglobulin G Inactivated vaccine independent predictor independent predictors levels of antibody Limited Messenger RNA Odds ratio participant Participants prospective cohort study Quantitative questionnaire RBD reduction respiratory risk SARS-CoV-2 second dose Seropositivity severe acute respiratory syndrome Coronavirus single booster dose the median Turkey university hospital vaccination Vaccine waning immunity were infected were measured [DOI] 10.1002/jmv.27620 PMC 바로가기 [Article Type] Article
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccineBNT162b2 및 AZD1222 백신의 첫 번째 접종 후 WM, CLL 및 NHL 환자에서 낮은 중화 항체 반응Article Published on 2022-05-012022-09-12 Journal: Clinical and experimental medicine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age and gender antibodies AZD1222 BNT162b2 booster doses chronic chronic lymphocytic leukemia CLL Control COVID-19 Efficacy first dose Hematological malignancy investigated IQR Macroglobulinemia malignant disease NAb NAb titer NAbs neutralizing antibody Neutralizing antibody response NHL Non-Hodgkin Lymphoma Patient performed response SARS-CoV-2 the median the vaccine treatment initiation vaccination Vaccine Waldenstrom Macroglobulinemia. [DOI] 10.1007/s10238-021-00746-4 PMC 바로가기 [Article Type] Article
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA VaccinationBNT162b2 COVID-19 mRNA 백신 접종 후 6개월 후의 SARS-CoV-2 변이체에 대한 백신 유도 항체 반응Article Published on 2022-04-272022-09-11 Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Alpha anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody antibody levels Beta BNT162b2 BNT162b2 vaccine booster dose booster doses collected coronavirus COVID-19 COVID-19 disease COVID-19 mRNA vaccine COVID-19 mRNA vaccines D614G decrease Delta delta variant detectable dose effective Efficacy Eta fold Health care Health care worker immune evasion immune responses Lineage Month mRNA mRNA vaccine mRNA vaccines neutralization neutralize neutralized Neutralizing Neutralizing antibodies new virus of BNT162b2 persistence postvaccination raised receiving reduced reduction respiratory response responses SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein SARS-CoV-2 variant sera severe acute respiratory syndrome Coronavirus severe COVID-19 disease specific antibodies Transmissibility vaccination Vaccination strategies Vaccination strategy Vaccine vaccine efficacy vaccinees Vaccines variant variants [DOI] 10.1128/spectrum.02252-21 PMC 바로가기 [Article Type] Article
Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers실생활에서 코로나백의 약화 효과: 의료 종사자를 대상으로 한 후향적 코호트 연구Article Published on 2022-04-202022-09-11 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI adjusted Alpha Alpha variant association booster dose booster doses clinical trials conducted CoronaVac COVID-19 COVID-19 disease COVID-19 infection COVID-19 infections COVID-19 vaccine Cox regression defined demonstrated determine dominant dose doses Effectiveness follow-up period groups Health care Health care worker health care workers Inactivated vaccine incidence rate İstanbul positive PCR test rate ratio receive receiving reduce retrospective cohort study SARS-COV-2 infection second dose test result the vaccine Turkey university hospital vaccination Vaccine vaccine effectiveness variant variants were used [DOI] 10.1016/j.vaccine.2022.03.032 PMC 바로가기 [Article Type] Article
Sustaining Maternal and Neonatal Tetanus Elimination (MNTE) in countries that have been validated for elimination – progress and challenges제거가 검증된 국가의 산모 및 신생아 파상풍 제거(MNTE) 지속 – 진행 상황 및 과제Article Published on 2022-04-082024-07-28 Journal: BMC Public Health [Category] 백일해, 파상풍, [키워드] booster doses disease elimination sustainability Tetanus vaccination vaccine preventable diseases [DOI] 10.1186/s12889-022-13110-2 PMC 바로가기
Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers의료 종사자에서 비활성화된 COVID-19 백신의 안전성 및 면역원성Article Published on 2022-04-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] administration adverse event Adverse reaction Adverse reactions age antibodies antibody Antibody Response Antibody responses appear booster doses comparable Concentration conducted convalescent plasma convalescent serum CoronaVac coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine domain dose Effective vaccines geometric mean geometric mean concentration GMC Health care Health care worker health care workers hospital IgG immunization immunogenicity Immunoglobulin Immunoglobulin G inactivated Inactivated vaccine incidence Infection injection Injection-site pain Local myalgia N protein nucleocapsid nucleocapsid protein Pain pandemic participant positive prospective cohort study Protein RBD Receptor-binding domain recruited regimen Safe Safety SARS-CoV-2 Serious Adverse Event Serious Adverse Events seroconversion rate seroconversion rates Spike protein tested the RBD Total total antibodies total antibody U/mL Vaccine virus waned [DOI] 10.1002/jmv.27458 PMC 바로가기 [Article Type] Article
Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant델타 변이형이 우세하기 전과 우세한 기간 동안 미군 병사들 사이에서 mRNA-1273, BNT162b2 및 JNJ-78436735 COVID-19 백신의 효과Article Published on 2022-04-012022-09-11 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Antigen B.1.617.2 BNT162b2 booster dose booster doses case-control study Chain Reaction circulation Cohort conducted confounders Control COVID-19 COVID-19 vaccination COVID-19 vaccine decrease Defense defined Delta delta variant Department Effectiveness evaluated highest Hospitalization individual individuals JNJ-78436735 Laboratory logistic regression model lowest male median age mRNA mRNA-1273 mRNA-1273 vaccine Odds ratio outcome outcomes performed polymerase chain polymerase chain reaction positive SARS-CoV-2 delta SARS-COV-2 infection SARS-CoV-2 test significantly higher significantly lower stratified Support Surveillance symptomatic infection Symptoms test result the SARS-CoV-2 vaccination Vaccine variant variants of SARS-CoV-2 [DOI] 10.1001/jamanetworkopen.2022.8071 PMC 바로가기 [Article Type] Article